BDX.AX ASX
BCAL Diagnostics Limited
1W: +7.4%
1M: +26.1%
3M: +20.8%
YTD: -27.5%
1Y: +33.9%
3Y: -11.2%
5Y: -56.5%
A$0.09 ($0.06)
+0.00 (+4.60%)
Weekly Expected Move ±16.7%
A$0
A$0
A$0
A$0
A$0
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Smart Money Score
No convergence signal
Key Statistics
Market CapA$32.1M ($22.3M)
52W Range0.052-0.155
Volume360,690
Avg Volume300,698
Beta0.81
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAnne-Louise Arnett
Employees6
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2021-07-21
Websitebcaldiagnostics.com
50 Clarence Street
Sydney, NSW 2000
AU
Sydney, NSW 2000
AU
61 2 9078 7671
About BCAL Diagnostics Limited
BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring. This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.
Latest News
No recent news
Recent Insider Trades
No insider trades found